

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – October 31, 2006

NOTICE OF STATUS CHANGE

This study is temporarily suspended to patient accrual effective Tuesday, October 31, 2006. Accrual to dose level 0 has been met.

Please retain this notice with the protocol.